News
ABUS
2.580
-1.15%
-0.030
This Analyst Says Arbutus' EASL Presentations Outline Path For A Functional Cure For Chronic Hepatitis B
JMP Securities reiterates its Market Outperform rating but reduces the price target to $9 from $10 on Arbutus Biopharma Corp (NASDAQ: ABUS) after data presentation at the European Association for the Study of the Liver International Liver Congress. The ana...
Benzinga · 19h ago
--JMP Securities Adjusts Arbutus Biopharma Price Target to $9 From $10, Maintains Market Outperform Rating
MT Newswires · 1d ago
Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical Update
AB-729, our RNAi therapeutic, provided robust and comparable HBsAg declines in both HBeAg+ and HBeAg- patients 50% (16 out of 32) of patients maintained HBsAg levels below 100 IU/mL 24 weeks after their last AB-729 dose In the first five patients who disco...
GlobeNewswire · 4d ago
Arbutus to Present Seven Scientific Posters at EASL International Liver Congress™ 2022
Conference Call & Webcast to discuss new data being presented at EASL ILC 2022 scheduled for June 27, 2022 at 8:00 am ETWARMINSTER, Pa., June 08, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical comp...
GlobeNewswire · 06/08 06:05
We Think Arbutus Biopharma (NASDAQ:ABUS) Can Easily Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Simply Wall St. · 06/06 18:45
Arbutus and Vaccitech begin trial testing combo therapy for chronic hepatitis B virus treatment
Arbutus Biopharma (NASDAQ:ABUS -1.5%) and Vaccitech (NASDAQ:VACC) had begun dosing first patient in a Phase 2a trial testing Arbutus’ RNAi therapeutic candidate, AB-729, in combination with Vaccitech’s T-cell stimulating immunotherapeutic, VTP-300, and sta...
Seekingalpha · 06/06 13:43
Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus
Trial will evaluate AB-729, an RNAi therapy in combination with VTP-300, an immunotherapeutic, and NA therapyWARMINSTER, Pa. and OXFORD, United Kingdom, June 06, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopha...
GlobeNewswire · 06/06 11:32
Arbutus And Vaccitech Dose First Patient In Phase 2a Clinical Trial Combining Therapies For The Treatment Of Chronic Hepatitis B Virus
Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, and Vaccitech plc
Benzinga · 06/06 11:31
Arbutus to Participate in June Investor Conferences
WARMINSTER, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today...
GlobeNewswire · 06/02 11:30
Arbutus Announces Abstract Selected for Publication at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
WARMINSTER, Pa., May 26, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today ...
GlobeNewswire · 05/26 21:05
Pennsylvania Biotech Center's economic impact grows to $7B as it expands in Bucks County, report finds
The Pennsylvania Biotechnology Center of Bucks County and its affiliated organizations have generated an economic impact of $7.3 billion for the state during the past six years, according to a new study. The analysis, conducted by KLIOS Consulting economi...
American City Business Journals · 05/20 19:04
Arbutus to Present at H.C. Wainwright Global Investment Conference
WARMINSTER, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today ...
GlobeNewswire · 05/17 11:30
Morning Brief: Top Financial Stories Dominating on Monday, May 9
CNBC Ford Motor Selling 8M Shares Of Rivian Automotive
Benzinga · 05/09 12:29
Moderna Files Motion To Dismiss COVID-19 Vaccine Related Patent Claims: WSJ
Moderna Inc (NASDAQ: MRNA) is trying to fight off rival companies’ patent infringement claims related to its COVID-19 vaccine, arguing that the companies may only pursue their claims by seeking royalties from the federal government.
Benzinga · 05/09 12:16
Arbutus Biopharma: Q1 Earnings Insights
  Arbutus Biopharma (NASDAQ:ABUS) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
Benzinga · 05/05 13:32
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
Arbutus (ABUS) delivered earnings and revenue surprises of 15.38% and 118.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 12:55
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/05 12:43
Arbutus Biopharma GAAP EPS of -$0.11 beats by $0.05, revenue of $12.58M beats by $8.16M
Arbutus Biopharma press release (NASDAQ:ABUS): Q1 GAAP EPS of -$0.11 beats by $0.05. Revenue of $12.58M (+496.2% Y/Y) beats by $8.16M. As of March 31, 2022, the company had cash,
Seekingalpha · 05/05 11:47
BRIEF-Arbutus Reports First Quarter 2022 Financial Results
reuters.com · 05/05 11:44
Arbutus Biopharma Q1 EPS $(0.11) Beats $(0.16) Estimate, Sales $12.58M Beat $4.37M Estimate
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.16) by 31.25 percent. This is a 47.62 percent increase over losses of $(0.21) per share from
Benzinga · 05/05 11:37
More
Webull provides a variety of real-time ABUS stock news. You can receive the latest news about Arbutus Biopharm through multiple platforms. This information may help you make smarter investment decisions.
About ABUS
Arbutus Biopharma Corporation is a clinical-stage, biopharmaceutical company. The Company is focused on virology capabilities to develop therapeutics that target specific viral diseases. The Company’s focus areas include Hepatitis B virus (HBV), SARS-CoV-2 and other coronaviruses. In HBV, the Company is developing a ribonucleic acid interference (RNAi) therapeutic, oral capsid inhibitor, an oral PD-L1 inhibitor, and oral RNA destabilizer that it intends to combine to provide a functional cure for patients with chronic HBV infection (cHBV) by suppressing viral replication, reducing surface antigen and reawakening the immune system. Its lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening and is being evaluated in multiple Phase II clinical trials. The Company is having an ongoing drug discovery and development program directed at identifying orally active agents for treating coronaviruses (including SARS-CoV-2).